Beth Israel Deaconess Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Beth Israel Deaconess Medical Center sits in the top decile of US sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count).

488 total trials 66 currently recruiting 321 completed early-phase tilt top decile by trial count

Beth Israel Deaconess Medical Center: 488 sponsored US clinical trials, 66 recruiting.

Beth Israel Deaconess Medical Center sponsors 488 registered US clinical trials on ClinicalTrials.gov, 66 of them currently recruiting, and 321 completed. 45 of these trials are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 8 trials.

Top-decile sponsor footprint

Beth Israel Deaconess Medical Center ranks in the top decile of sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

321 of 380 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

488 total, page 8 of 10

COMPLETED Phase 1

Thiamine as a Metabolic Resuscitator in Septic Shock

NCT01070810

COMPLETED Phase 1

Trichuris Suis Ova in Peanut and Tree Nut Allergy

NCT01070498

COMPLETED

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

NCT01288963

TERMINATED Phase 1

Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)

NCT01504945

COMPLETED Phase 1

Tissue Oxygenation Measurements With Modulated Light (S-FLARE)

NCT01116297

COMPLETED NA

Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment

NCT01605448

COMPLETED Phase 1

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361

TERMINATED Phase 4

Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery

NCT01149616

TERMINATED Phase 1

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

NCT00622401

COMPLETED NA

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

NCT01165983

COMPLETED NA

Progressive Resistance Training in Patients With Class III Obesity

NCT01100450

COMPLETED NA

Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease

NCT01294033

COMPLETED NA

Regulation of FGF21 by Nutritional Challenges

NCT00968747

COMPLETED NA

Exercise Program in Women With Metabolic Syndrome

NCT00929500

COMPLETED

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

NCT03103425

COMPLETED NA

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

NCT01624727

COMPLETED Early Phase 1

Objective Flap Assessment During Reconstructive Surgery

NCT00952107

COMPLETED Phase 2

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293

COMPLETED Phase 2

The Effects of DHA on Periodontitis

NCT01976806

COMPLETED NA

Electronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly Patients

NCT01313169

COMPLETED Phase 2

Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

NCT00908960

COMPLETED NA

Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study

NCT00906581

COMPLETED NA

Serum Markers in Gluten Challenge

NCT00931892

COMPLETED Phase 2

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

NCT00782275

COMPLETED Phase 2

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

NCT00827359

TERMINATED Phase 2

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

NCT00866723

COMPLETED NA

Utility Analysis of an Endoscopy Follow-up System

NCT01172080

COMPLETED

Physical Health in Midlife: Influences of Adversity and Relationships Over Time

NCT01853332

COMPLETED

Near Infrared Spectroscopy (St02)

NCT01062685

COMPLETED NA

Alcohol and Atherosclerosis Pilot Study

NCT00786279

COMPLETED Phase 4

The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache

NCT00719134

COMPLETED NA

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00801320

COMPLETED NA

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

NCT00749320

COMPLETED Phase 2

Leptin in the Maintenance of Reduced Body Weight

NCT01155180

COMPLETED

Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis

NCT00705848

COMPLETED Phase 1

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

NCT00598572

COMPLETED

Gas Embolism With Use of Argon Plasma Coagulation

NCT00676858

COMPLETED Phase 1

Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer

NCT00721370

COMPLETED Phase 1

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

NCT00697684

COMPLETED

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235

COMPLETED

Endothelium in Severe Sepsis

NCT00793442

COMPLETED NA

Effects of Dietary Manipulation on Metabolism in Healthy Adults

NCT00476125

COMPLETED Phase 1

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

NCT00631072

COMPLETED Phase 3

Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia

NCT00903266

COMPLETED Phase 2

Statin Therapy in the Treatment of Sepsis

NCT00676897

COMPLETED NA

Cerebellar rTMS for the Treatment of Schizophrenic Patients

NCT01072617

COMPLETED Phase 2

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

NCT00780962

COMPLETED Phase 1

Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest

NCT00676585

COMPLETED NA

Effect of Low Tidal Volume Ventilation in Improving Oxygenation and Thus Reducing Acute Lung Injury in the Cardiac Surgical Patient

NCT00538161

COMPLETED

Outcomes of a Deep Inferior Epigastric Perforator Flap Program

NCT00543907

← Previous Page 8 of 10 Next →

Phase Distribution

PhaseTrial count
Phase 1 53
Phase 2 91
Phase 3 13
Phase 4 32

What is open in the Beth Israel Deaconess Medical Center pipeline

66 recruiting of 488 indexed (14% open); 321 completed (66%).

Phase mix: 45 late (III/IV) vs 144 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Beth Israel Deaconess Medical Center: open-pipeline peers nationwide

Peers matched on 488 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18% Total trials Recruiting share Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)H. Lee Moffitt Cancer Center and Research InstituteCase Comprehensive Cancer CenterWayne State UniversityUniversity of MichiganAlbany Medical College
Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 488 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Beth Israel Deaconess Medical Center page

488 registered trials is a research-attention snapshot, not an endorsement of Beth Israel Deaconess Medical Center or any single study.

  • 66 of Beth Israel Deaconess Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Beth Israel Deaconess Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Beth Israel Deaconess Medical Center pipeline card: 488 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.